MYCAMINE
What it isEchinocandin inhibiting fungal beta-1,3-glucan synthesis; invasive candidiasis.
Why this oneIts labeled Candida-prophylaxis role in stem-cell transplantation distinguishes it from other echinocandins.
What limits itNo CNS or urinary penetration, so it fails in meningitis and cystitis. Not active against Aspergillus alone.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Candidemia, acute disseminated candidiasis, Candida peritonitis/abscesses | Adult | 100 mg QD | 100 mg QD | 100 mg QD |
| Candidemia/disseminated candidiasis/peritonitis/abscesses | Peds ≥4 mo | 2 mg/kg QD | 2 mg/kg QD | 100 mg/day |
| Candidemia/disseminated (without meningoencephalitis/ocular dissem.) | Peds <4 mo | 4 mg/kg QD | 4 mg/kg QD | |
| Esophageal candidiasis | Adult | 150 mg QD | 150 mg QD | 150 mg QD |
| Esophageal candidiasis | Peds ≥4 mo | 3 mg/kg QD (≤30 kg); 2.5 mg/kg QD (>30 kg) | 150 mg/day | |
| Prophylaxis of Candida in HSCT recipients | Adult | 50 mg QD | 50 mg QD | 50 mg QD |
| Prophylaxis of Candida in HSCT recipients | Peds ≥4 mo | 1 mg/kg QD | 50 mg/day |
Renal No adjustment needed
Hepatic No adjustment needed
Pregnancy May cause fetal harm based on animal data (visceral abnormalities, abortion in rabbits); insufficient human data
Lactation No human data; present in rat milk; weigh benefits against maternal need
NO BOXED WARNINGS
Principal riskNo CNS or urinary penetration
Cost, est. cash$20–$1,500/dose or month
Generic entry2019
Legacy pregnancy categoryC
Defining liabilityHepatotoxicity and clinically important CYP/QT interactions; organ toxicity varies markedly by agent.
